EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

NAFLD SUMMIT 2019

 

26-28 September 2019 Seville
Close
N. Poster
Poster title
Applicant name
Status
  P06-01 miR-34a is strongly activated in human and experimental NAFLD, correlating with key disease hallmarks André Simão Received Received
  P03-01 Obese patients carrying NAFLD-associated genetic variants present specific serum and liver lipidomic profiles: identification of a lipidomic signature in serum to estimate the liver fat content. Pedro Miguel Rodrigues Received Received
  P04-01 A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors Anna Mantovani Received Received
  P02-01 Berberis Aristata, Elaeis Guineensis and Coffea Canephora extracts modulate the Insulin Receptor expression and improve hepatic steatosis in NAFLD patients: a pilot study Valentina Cossiga Received Received
  P01-01 Pilot study of liraglutide on weight and enzymes of obese patients with NAFLD Amr Asem Elfert Received Received
  P05-01 Alcohol and other contributing factors to the burden of liver disease among patients with type-2 diabetes mellitus: a retrospective longitudinal study Lucia PARLATI Received Received
  P01-02 RIP3-dependent signalling impacts on lipid metabolism and halts disease progression in experimental non-alcoholic fatty liver disease Marta B. Afonso Received Received
  P04-02 Risk factors in type 2 diabetic mellitus patients Ruxandra-Georgeta Mare Received Received
  P06-02 Regulation of magnesium homeostasis through CNNM4 modulation resolves NAFLD Jorge Simón Received Received
  P05-02 Changes in individual free fatty acids during an oral glucose tolerance test in non-alcoholic fatty liver disease subjects stratified by body mass index Bárbara Patrício Received Received
  P02-02 The economic burden of patients diagnosed with non-alcoholic steatohepatitis in France, Germany, Italy, Spain and the United Kingdom in 2018 Sandrine Cure Received Received
  P03-03 Estimated GFR is associated with PNPLA3 risk variant p.I148M in patients with non-alcoholic fatty liver disease Marcin Krawczyk Received Received
  P06-03 Serum adenosine deaminase values are associated with advanced liver disease in patients with Non-Alcoholic Fatty Liver Disease Emmanouil Sinakos Received Received
  P01-03 Co-creating Comics to Communicate Non-Alcoholic Fatty Liver Disease - A participatory Research Approach Mireia Alemany i Pagès Received Received
  P05-03 Early immunological modifications of the intestinal barrier in response to a non-alcoholic steatohepatitis-inducing diet Simon Peschard Received Received
  P04-03 Psoriasis and liver damage in HIV-infected subjects M Luisa Montes Ramírez Received Received
  P02-03 Cardiovascular risk assessment in a non-alcoholic fatty liver disease group of romanian patients Dascalu Daciana Nicoleta Received Received
  P03-04 Cannabis consumption prevents hepatic steatosis in psychosis patients PAULA IRUZUBIETA Received Received
  P01-04 Decreased expressions of p70S6K in NK cells of NAFLD patients inhibited F-actin and was correlated with their impaired function Johnny Amer Received Received
  P05-04 The efficacy of L-carnitine administration in nonalcoholic fatty liver disease patients Vasyl Prysyazhnyuk Received Received
  P04-04 Predictive circulating hormone biomarkers for NAFLD patient stratification Vanda Marques Received Received
  P02-04 Is diabetes mellitus associated with hepatocellular carcinoma in patients with chronic liver disease of non viral etiology?: A case control study Ravi Daswani Received Received
  P06-04 Diagnostic performance of three non-invasive fibrosis scores (Hepamet, Fib-4, Nafld Score) on NAFLD in a mixed Brazilian population Claudia Oliveira Received Received
  P01-05 High prevalence of fatty liver in diabetes: comparison between ecographic and biochemical diagnostic methods Rita Andrade Received Received
  P03-05 Triple targeting of nuclear receptors protects against diet-induced NAFLD in mice Tawhidul Islam Received Received
  P05-05 A deep learning algorithm to quantify liver fat content in humans Sami Qadri Received Received
  P02-05 Picroside II protects FFA-induced lipid accumulation and lipotoxicity in an in-vitro model of NAFLD Hiteshi Dhami-Shah Received Received
  P06-05 Establishment of a 3D human liver model to recapitulate NASH progression in vitro Simon Stroebel Received Received
  P04-05 Relationship of semiquantitative scoring systems with computered-assisted digital image analysis for quantification of histological features in NAFLD David Marti-Aguado Received Received
  P05-06 The effect of subclinical hypothyroidism on cardiovascular aging in individuals with non-alcoholic fatty liver disease Anastasiia Radchenko Received Received
  P06-06 Evaluating accuracy of serum steatosis and fibrosis scores in a cohort of morbid obese patients Moira Testa Received Received
  P02-06 Liver damage in nonalcoholic fatty liver disease: Changes in stearoyl-CoA-desaturase index and metalloproteinase activity Laura Giuseppina Di Pasqua Received Received
  P01-06 High risk of non-alcoholic fatty liver disease and significant liver fibrosis in patients with hidradenitis suppurativa Maria Teresa Arias Loste Received Received
  P04-06 The role of adipocyte-derived extracellular vesicles in the development of NAFLD Johanna Matilainen Received Received
  P03-06 Mitochondrial DNA Analysis in NASH patients Maciej Jablkowski Received Received
  P02-07 Effect of obeticholic acid on liver function in patients with fibrosis due to NASH Alicia Meli Received Received
  P04-07 PNPLA3 gene polymorphism (rs738409) and non-alcoholic fatty liver disease risk in women with polycystic ovary syndrome Amanda Medeiros Recuero Received Received
  P06-07 Circulating mir-192-5p as a novel biomarker for liver fibrosis progression to cirrhosis Lisa Tran Received Received
  P05-07 Omitted liver disease screening in acute screening coronary syndrome hides prevalence of high levels of severe liver fibrosis Rebecca Reynolds Received Received
  P01-07 Hyperferritinemia and long-term outcomes in NAFLD patients. A longitudinal multicenter study. Angelo Armandi Received Received
  P03-07 High-throughput sequencing identified miR-193a as a potential biomarker of non-alcoholic fatty liver disease activity Katherine Johnson Received Received
  P02-08 Differential effects of palmitic acid on the development of NASH and related metabolic disorders Olga Estévez Vázquez Received Received
  P03-08 BTT-105 ameliorates non-alcoholic steatohepatitis on diet induced animal models and attenuated lysophosphoatidic acid induced hepatic stellate cell activation. Dae Won Jun Received Received
  P04-08 Metagenomics and molecular phenomics of obesity and hepatic steatosis Stijn Meijnikman Received Received
  P01-08 High fat-high sucrose diet promotes liver disease progression and defective metabolic adaptation Gerard Baiges Received Received
  P06-08 Non-electrophilic activation of the NRF2 pathway ameliorated experimental Nonalcoholic Steatohepatitis Carmen Valcarce Received Received
  P01-09 Liver fibrosi but not PNPLA3 mutation is associated with decreased renal function in non-alcoholic fatty liver disease francesco baratta Received Received
  P03-09 Saroglitazar, a potential treatment for Non-Alcoholic Fatty Liver Disease/ Non-Alcoholic Steatohepatitis: Preliminary evidence from pre-clinical, clinical and real world studies Manjunath K Received Received
  P06-09 Dietary switch and exercise differentially resolove NASH and fibrosis Anita M. Van Den Hoek Received Received
  P02-09 Deletion of Keap1 and L-in in mice protects from NAFLD progression Sreepradha Eswaran Received Received
  P05-09 lncRNA-H19 as an epigenetic biomarker of liver cancer stem cells Ángela Rojas Received Received
  P04-09 Physical activity removes the harmful effects of sedentary behaviours: a prospective look to the Horizon 2020 Foie Gras project in Southern Italy. Emilio Molina Molina Received Received
  P02-10 The relationship of systemic inflammation and endothelial dysfunction with blood lipid spectrum and adipokines levels in patients with NAFLD Iryna Fedzhaga Received Received
  P04-10 miRNAs as non-invasive biomarkers in Non-alcoholic Fatty Liver Disease (NAFLD) Rocío Montero-Vallejo Received Received
  P01-10 Plasma glycine concentration is inversely associated to hepatic and anabolic insulin resistance in subjects with NAFLD Chiara Barbieri Received Received
  P05-10 NAFLD population in Northern and Southern Italy. A longitudinal and epidemiological study in four tertiary centers. Ramy Younes Received Received
  P03-10 Validation of a simple 2 step strategy involving FIB4 and mre in evaluation of non alcoholic fatty liver disease Swati Kaamble Received Received
  P06-10 Oxidized-LDL as a marker of oxidative stress is strongly related to NASH irrespectively of insulin resistance and liver fibrosis Rocío Gallego-Durán Received Received
  P02-11 Effect of elafibranor treatment and dietary intervention in the Gubra Amylin NASH (GAN) diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis Michael Feigh Received Received
  P04-11 Inhibition of alpha 2A adrenergic receptors reduces liver inflammation and fibrosis in experimental NASH Raj Mookerjee Received Received
  P03-11 Fasting Refeeding HFD Mice Accumulate Hepatic Lipid and Develop Metabolic Dysfunction which Control by NQO1 Enzymatic Action Dipendra Khadka Received Received
  P01-11 Increased hepatic Angiopoietin-Like Protein 3 is associated with NAFLD and with liver expression of vitamin D receptor and vitamin D hydroxylases Ilaria Barchetta Received Received
  P06-11 Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment Axelle Louard Received Received
  P05-11 Differences in anxiety and depressive symptomatology of NAFLD/NASH patients according to fibrosis stage Jesús Funuyet-Salas Received Received
  P06-12 A high-cholesterol diet promotes steatohepatitis and liver tumorigenesis in HCV core gene transgenic mice Xiaojing Wang Received Received
  P02-12 Mitochondrial GNMT-complex II interaction is recovered by miR-873-5p targeting in NAFLD David Fernández Ramos Received Received
  P04-12 Early diagnosis of fibrosis in non - alcoholic fatty liver disease Saidrakhim Lukmonov Received Received
  P01-12 The role endothelial lipase in patients with non-alcoholic fatty liver disease and hypertension depending on the performance of the lipid profile Anna Bashkirova Received Received
  P05-12 Nover 3D Human NASH model for high-throughput compatible efficacy testing Simon Stroebel Received Received
  P03-12 HSD17B13 and PNPLA3 gene variants exert opposite effects on non-alcoholic fatty liver phenotypes: results from the real life FLAG cohort Marcin Krawczyk Received Received
  P06-13 Changes in autophagic flux in diet-induced non-alcoholic fatty liver disease and hepatic fibrosis models in C57Bl/6 mice. Christine Yee Received Received
  P03-13 Urea cycle enzymes dysregulation is linked to a more agressive NAFLD phenotype Rocío Gallego-Durán Received Received
  P02-13 Impact of BMI and Ethnicity on histology as assessed by automated quantitation in liver biopsies of patients with NAFLD Roberta Forlano Received Received
  P01-13 The genetic background strongly influences the development of steatohepatitis and metabolic syndrome in a novel experimental model of dual ASH/NASH Raquel Benedé Ubieto Received Received
  P04-13 S-adenosylmethionine alleviates hepatic steatosis via alternation of lipid- and bile acid-metabolism and microbiota Makoto Nakamuta Received Received
  P05-13 Elevated expressions of Sodium taurocholate co-transporting polypeptide (NTCP) on NK cells impaired their function and contribute to liver fibrosis in NAFLD patients Ahmed Salhab Received Received
  P05-14 Combined treatment with L-carnitine and nicotinamide riboside improves hepatic metabolism and attenuates obesity, hepatic peroxidation and steatosis kanita salic Received Received
  P06-14 The smoking-hemoglobin interaction and risk for advanced fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease Yusuf Yilmaz Received Received
  P02-14 A translational mouse model for NASH and advanced fibrosis in association with atherosclerosis Anita M. Van Den Hoek Received Received
  P01-14 Selective modulation of mGlu5 receptor affects oleic and palmitic acid-induced steatosis in HepG2 cells CLARISSA BERARDO Received Received
  P04-14 Moderate alcohol consumption is associated with higher grade of liver fibrosis in patients with non-alcoholic fatty liver disease Lorenzo Mulazzani Received Received
  P03-14 The features of gut microbiota composition in patients with NAFLD Khrystyna Kvit Received Received
  P06-15 Ductular Reaction Predicts the Progression of Non-Alcoholic Fatty Liver Disease Ramy Younes Received Received
  P02-15 Gut microbiota composition in patients with nonalcoholic fatty liver disease Khrystyna Kvit Received Received
  P05-15 acNASH Index: A Novel Screening Tool For Nonalcoholic Steatohepatitis Patients With Persistent Normal Alanine Aminotransferase Kenneth Iden Zheng Received Received
  P03-15 Nuclear NFATc1 regulates pro-apoptotic ER stress signaling protein CHOP, and progresses NAFLD to NASH Muhammad Umair Latif Received Received
  P04-15 circulating pcsk9 levels correlated with advanced disease in patients with biopsy-proven non alcoholic fatty liver disease Rocío Muñoz Hernández Received Received
  P01-15 Liraglutide improves NASH and metabolic disorders in a 3-week diet-induced NASH mouse model Francois Briand Received Received
  P06-16 Coping strategies and fibrosis: a psychological approach to NAFLD Jesús Funuyet-Salas Received Received
  P02-16 Propionic acid intervention in obese Ldlr-/-.Leiden mice attenuates NASH development, but negatively affects cognition Eveline Gart Received Received
  P04-16 The co-stimulatory signals mediated by icos-icosl dyad promote the evolution of non-alcoholic steatohepatitis (nash) Naresh Naik Ramavath Received Received
  P01-16 Genes involved in the bile acid transport and metabolism and their contribution to disease predisposition in a cohort of children with biopsy-proven NAFLD Teresa Brunetti Received Received
  P05-16 PNPLA3 could help the clinicians to individuate NAFLD subjects at major risk of disease progression: a single center cohort study Antonio Salvati Received Received
  P03-17 Function of PX as a novel NOX4 regulator in nonalcoholic steatohepatitis Hye-Eun Lee Received Received
  P06-17 Network-based drug-repositioning platform identifies pharmacological compounds with anti-steatogenic mode of action Danae Zareifi Received Received
  P05-17 IDL-2965: A ive, highly potent, clinical stage integrin antagonist for the treatment of NASH Scott Seiwert Received Received
  P02-17 Comparing computerized tomography indices and liver biopsy in liver transplantation donors for hepatosteatosis Genco Gencdal Received Received
  P01-17 Targeting liver Glutaminase 1 ameliorates NASH by restoring hepatic very-low density lipoproteins triglyceride assembly Jorge Simón Received Received
  P04-17 FAST score for identification of patients with non-alcoholic steatohepatitis (NASH), NAS=4 and significant (F=2) or advanced (F=3) fibrosis Laura Cantu Sanchez Received Received
  P01-18 In patients with Nonalcoholic Fatty Liver Disease significant fibrosis and the active nonalcoholic steatohepatitis is associated with a moderate-high cardiovascular risk at 10 years. Paola Casciato Received Received
  P03-18 Differential therapeutic effects of single and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophage biology Sander Lefere Received Received
  P04-18 Ablation of High mobility group box-1 in intestinal epithelial cells causes intestinal lipid accumulation and reduced non-alcoholic steatohepatitis Natalia Nieto Received Received
  P05-18 NEDDylation inhibition as a new potential therapy for Non Alcoholic Fatty Liver Disease Marina Serrano-Macia Received Received
  P02-18 Transcriptomic and epigenetic characterization of a NAFLD murine model Antonio Gil-Gómez Received Received
  P06-18 Intestinal microbiota and fecal short chain fatty acids in children with non-alcoholic fatty liver disease Nataliya Zavhorodnia Received Received
  P06-19 PNPLA3 rs738409 Gene Variant Aggravates Kidney Tubular Injury Among NAFLD Population with Persistent Normal Alanine Aminotransferase Kenneth I. Zheng Received Received
  P05-19 Predictors of high shear wave elastography (SWE) measurements among nonalcoholic fatty liver disease (NAFLD) patients in primary care Abdel-Aziz Shaheen Received Received
  P03-19 GLI-3 mutation influences weight gain, glucose tolerance and hepatic innate immune populations in a model of non-alcoholic fatty liver disease Jiawei Li Received Received
  P04-19 Fibrosis impact on quality of life in non-alcoholic fatty liver disease (NAFLD) Jesus Funuyet-Salas Received Received
  P02-19 Osteopontin deficiency promotes liver senescence mediating the onset of non-alcoholic fatty liver disease during aging Beatriz Gómez Santos Received Received
  P01-19 Efficacy and Safety of Saroglitazar in Management of NAFLD patients using Transient Elastography: A Single Center Observational Study Sujit Chaudhuri Received Received
  P01-20 Utility of applying age-adjusted FIB-4 cutoffs in patients with type 2 diabetes Stefano Ciardullo Received Received
  P02-20 Actions of the protease fibroblast activation protein alpha (FAP) on collagens and FGF21 and roles in chronic liver injury Mark Gorrell Received Received
  P05-20 Establishment of an novel non-alcoholic steatohepatitis model using a high fat and cholesterol diet in young rabbits Eiketsu Sho Received Received
  P04-20 Metabolic caracterization of hepatocellular cancer cells related to non-alcoholic fatty liver disease Claudia Oliveira Received Received
  P03-20 Effect of treatment with dulaglutide on metabolic function and liver tests in patients with NAFLD and diabetes mellitus type 2 Ekaterina Liusina Received Received
  P06-20 Myeloid Cells-Derived Osteopontin Protects from Diet-Induced Non-alcoholic Fatty Liver Disease in Mice Natalia Nieto Received Received
  P05-21 Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH Alicia Meli Received Received
  P02-21 The Vanin 1-Cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in non-alcoholic fatty liver disease Olivier Govaere Received Received
  P01-21 Impact of FAT10 on PPAR-alpha downregulation during NASH progression Ludivine Clavreul Received Received
  P03-21 Effect of metformin therapy on the clinical and functional state of the liver in patients with metabolic syndrome associated with non-alcoholic fatty liver disease. Saidrakhim Lukmonov Received Received
  P04-21 Genotyping rs738491 in the SAMM50 Gene May Increase Accuracy of Noninvasive Assessment for Nonalcoholic Steatohepatitis Kenneth I. Zheng Received Received
  P06-21 Intervention with HE-700 reduces the development of liver inflammation in obese HFD-treated Ldlr-/-.Leiden mice by ameliorating the build-up of hepatic cholesterol Martine C. Morrison Received Received
  P02-22 Risk stratification of patients with non-alcoholic fatty liver disease in primary care using a reflex testing algorithm of FIB-4 and Enhanced Liver Fibrosis Score David Harman Received Received
  P03-22 High cholesterol diet and high saturated fatty acid diet: Which is worse for the liver Makoto Nakamuta Received Received
  P01-22 Similarity of risk factors among individuals with fatty liver with or without harmful alcohol consumption in a healthy population Helena Cortez-Pinto Received Received
  P06-22 A preclinical study on the effect of an oral edaravone formula on NASH in a rabbit model Xin-Fu Zhou Received Received
  P05-22 Burden of non alcoholic fatty liver disease in helicobacter pylori infected dyspeptic patients, is it a far reaching implication? Hafiz Abdul Basit Siddiqui Received Received
  P04-22 results of life style modification on weight loss and factors of failure in nafld Meryem Oustani Received Received
  P04-23 Suboptimal metabolic control is a risk factor for liver disease progression in patients with type 2 diabetes mellitus Lucia Parlati Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30 Fri 8:30-15:00
02:29
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

NAFLD SUMMIT 2019

 

26-28 September 2019 Seville
HELP LINE
Manage Orders
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 16/09/2019 TO 26/09/2020
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                  
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 24/09/2019
Upload Poster
Upload Oral Presentation of Video
Upload
Poster
Upload Oral
Presentation or Video




PosterSessionOnline
Logo Draft
 
Logo Cert